Company research
Generation Bio Co.
CIK 1733294Updated Sep 26, 2026
Name history
Generation Bio Co. · through May 14, 2026
Filing activity
Latest filing
50 filings on record · 15-12G, SCHEDULE 13G/A, EFFECT, 4, POS AM, S-8 POS.
About the company
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 231,197,000Source | 374,758,000Source | 376,264,000Source | 476,771,000Source |
| Property, Plant and Equipment, NetUSD | 15,293,000Source | 25,799,000Source | 22,215,000Source | 25,886,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 76,301,000Source | 66,446,000Source | 93,171,000Source | 375,145,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,224,000Source | — | — | — |
| Assets, CurrentUSD | 192,903,000Source | 272,618,000Source | 287,016,000Source | 379,186,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,456,000Source | 4,294,000Source | 7,530,000Source | 4,041,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,310,000Source | 69,852,000Source | 59,208,000Source | 65,143,000Source |
| Other Assets, NoncurrentUSD | 539,000Source | 265,000Source | 1,699,000Source | 403,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 144,993,000Source | 171,630,000Source | 93,771,000Source | 95,025,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 7,000Source | 7,000Source | 6,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 789,083,000Source | 774,224,000Source | 727,335,000Source | 689,866,000Source |
| Retained Earnings (Accumulated Deficit)USD | -703,045,000Source | -571,377,000Source | -444,765,000Source | -308,126,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 159,000Source | 274,000Source | -83,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 86,204,000Source | 203,128,000Source | 282,493,000Source | 381,746,000Source |
| Liabilities and EquityUSD | 231,197,000Source | 374,758,000Source | 376,264,000Source | 476,771,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 35,055,000Source | 39,914,000Source | 19,150,000Source | 18,808,000Source |
| Operating Lease, Liability, CurrentUSD | 13,006,000Source | 8,120,000Source | 7,086,000Source | 4,608,000Source |
| Accounts Payable, CurrentUSD | 1,408,000Source | 2,346,000Source | 662,000Source | 2,023,000Source |
| Operating Lease, Liability, NoncurrentUSD | 80,554,000Source | 89,774,000Source | 74,621,000Source | 76,217,000Source |
| Other Liabilities, NoncurrentUSD | 223,000Source | — | — | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 10,582,000Source | 12,919,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 29,161,000Source | 41,942,000Source | — | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -131,668,000Source | -126,612,000Source | -136,639,000Source | -119,151,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,931,000Source | 5,263,000Source | 5,130,000Source | 4,532,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 14,609,000Source | 24,341,000Source | 24,452,000Source | 17,857,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -386,000Source | 1,087,000Source | -1,386,000Source | 1,756,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -88,563,000Source | -52,745,000Source | -102,448,000Source | -91,821,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 94,529,000Source | -9,698,000Source | -192,515,000Source | 193,047,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,401,000Source | 7,397,000Source | 8,801,000Source | 5,958,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 186,000Source | 565,000Source | 581,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 250,000Source | 35,817,000Source | 12,989,000Source | 214,671,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 78,453,000Source | 72,237,000Source | 98,863,000Source | 380,837,000Source |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 7,300,000Source | — | — | — |
| Share-based Payment Arrangement, ExpenseUSD | 14,609,000Source | 24,341,000Source | 24,452,000Source | 17,857,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | -237,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -27,000Source | -41,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | -63,197,000Source | — | — | — |
| General and Administrative ExpenseUSD | 37,780,000Source | 50,850,000Source | 44,464,000Source | 33,854,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | -115,000Source | 356,000Source | -83,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -131,668,000Source | -126,612,000Source | -136,639,000Source | -119,151,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -136,639,000Source | -119,151,000Source |
| Nonoperating Income (Expense)USD | 10,722,000Source | 11,951,000Source | 4,543,000Source | -50,000Source |
| Operating ExpensesUSD | 162,282,000Source | 144,467,000Source | 141,182,000Source | 119,101,000Source |
| Operating Lease, Impairment LossUSD | 45,800,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | 12,360,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 436,000Source | 546,000Source | 1,260,000Source | 3,750,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 19,892,000Source | 5,904,000Source | — | — |
| Operating Income (Loss)USD | -142,390,000Source | -138,563,000Source | -141,182,000Source | -119,101,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -131,668,000Source | -126,612,000Source | -136,639,000Source | -119,151,000Source |
| Earnings Per Share, BasicUSD per share | -1.98Source | -1.96Source | -2.35Source | -2.12Source |
| Earnings Per Share, DilutedUSD per share | -1.98Source | -1.96Source | -2.35Source | -2.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 66,624,249Source | 64,483,520Source | 58,114,893Source | 56,295,409Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 66,624,249Source | 64,483,520Source | 58,114,893Source | 56,295,409Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 37,780,000Source | 50,850,000Source | 44,464,000Source | 33,854,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -136,639,000Source | -119,151,000Source |
| Nonoperating Income (Expense)USD | 10,722,000Source | 11,951,000Source | 4,543,000Source | -50,000Source |
| Operating ExpensesUSD | 162,282,000Source | 144,467,000Source | 141,182,000Source | 119,101,000Source |
| Research and Development ExpenseUSD | 61,305,000Source | 93,617,000Source | 96,718,000Source | 85,247,000Source |
| Restructuring and Related Cost, Incurred CostUSD | 900,000Source | 7,000,000Source | — | — |
Filing attachments
gbio-20250812xex99d1.htm · 8-K · 2025-08-12
EX-99.1 2 gbio-20250812xex99d1.htm EX-99.1 Exhibit 99.1 CONFIDENTIAL Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell-driven autoimmune disea…
Read attachment ↗gbio-20250718xex99d1.htm · 8-K · 2025-07-18
EX-99.1 3 gbio-20250718xex99d1.htm EX-99.1 Exhibit 99.1 Generation Bio Announces 1-for-10 Reverse Stock Split CAMBRIDGE, Mass. - July 18, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company’s common stock (“Reverse Stock Split”), effective at 5:00 pm Eastern Time on July 21, 2025. …
Read attachment ↗gbio-20250507xex99d1.htm · 8-K · 2025-05-07
EX-99.1 2 gbio-20250507xex99d1.htm EX-99.1 Exhibit 99.1 Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA Lead target and portfolio strategy to be announced MY 2025 Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE…
Read attachment ↗gbio-20250313xex99d1.htm · 8-K · 2025-03-13
EX-99.1 2 gbio-20250313xex99d1.htm EX-99.1 Exhibit 99.1 Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases Lead target and indication to be announced MY 2025 Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Mar. 13, 2025 -- Generation Bio Co. (Nasdaq:GBIO), a biotec…
Read attachment ↗gbio-20250106xex99d1.htm · 8-K · 2025-01-06
EX-99.1 2 gbio-20250106xex99d1.htm EX-99.1 Exhibit 99.1 Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo - Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases - Company reorganization supports evolution of ctLNP-enabled strategy and b…
Read attachment ↗